A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
Public ClinicalTrials.gov record NCT00571675. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
Study identification
- NCT ID
- NCT00571675
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Ascenta Therapeutics
- Industry
- Enrollment
- 220 participants
Conditions and interventions
Conditions
Interventions
- AT-101, prednisone and docetaxel Drug
- placebo, prednisone and docetaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2007
- Primary completion
- Aug 31, 2010
- Completion
- Aug 31, 2010
- Last update posted
- Nov 8, 2010
2007 – 2010
United States locations
- U.S. sites
- 24
- U.S. states
- 13
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Colorado Springs | Colorado | — | — |
| Not listed | New Port Richey | Florida | — | — |
| Not listed | Ocoee | Florida | — | — |
| Not listed | Fishers | Indiana | — | — |
| Not listed | Burnsville | Minnesota | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Las Cruces | New Mexico | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Kettering | Ohio | — | — |
| Not listed | Eugene | Oregon | — | — |
| Not listed | Spartanburg | South Carolina | — | — |
| Not listed | Amarillo | Texas | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Denton | Texas | — | — |
| Not listed | Midland | Texas | — | — |
| Not listed | Paris | Texas | — | — |
| Not listed | Webster | Texas | — | — |
| Not listed | Fairfax | Virginia | — | — |
| Not listed | Norfolk | Virginia | — | — |
| Not listed | Kennewick | Washington | — | — |
| Not listed | Vancouver | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00571675, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2010 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00571675 live on ClinicalTrials.gov.